Updated on
Summary Swiss drug maker Novartis AG says EU had approved Afinitor for treatment of breast cancer.
Afinitor is already approved to treat various tumors of the pancreas, kidney and brain.The US Food and Drug Administration approved the pill-based drug earlier this month for use in combination with Aromasin for postmenopausal women with recurring hormone receptor positive breast cancer lacking the protein HER2.Novartis said Monday that the European Commissions approval was based on a trial of more than 700 patients showing those treated with the two drugs lived significantly longer before their disease progressed.The company said recently its annual sales of Afinitor could rise above the $1 billion mark with the new approvals.
